A comparison of five paediatric dosing guidelines for antibiotics

Shrey Mathur, Charlotte Jackson, Heather Urus, Isabelle Ziarko, Matt Goodburn, Yingfen Hsia, Sally Ellis & Mike Sharland

Objective To compare dosing guidance in the paediatric formularies of high- and middle-income countries for 32 commonly prescribed antibiotics on the World Health Organization’s (WHO’s) 2017 Model list of essential medicines for children.

Methods We identified paediatric antibiotic guidelines that were either widely used internationally or originated from countries in which antibiotic use has increased markedly in recent years (i.e. Brazil, China, India, the Russian Federation and South Africa).

Findings The study analysis considered five leading antibiotic guidelines: (i) the Manual of childhood infections: the blue book; (ii) the BNF (British national formulary) for children; (iii) the Red book: 2018–2021 report of the committee on infectious diseases; (iv) WHO’s Pocket book of hospital care for children; and (v) Indian National treatment guidelines for antimicrobial use in infectious diseases. There was marked heterogeneity in the recommended dosing (i.e. daily dose, age dosing bands and dose frequency) for most commonly used antibiotics. The rationale for dosing recommendations was generally unclear.

Conclusion The pharmacokinetic, pharmacodynamic and clinical evidence supporting paediatric antibiotic dosing, particularly on total doses and on age or weight dosing bands, needs to be improved. Future research should consider whether the variations in guidance identified stem from different clinical disease patterns, varying levels of antibiotic resistance or drug availability rather than historical preferences. Interested global parties could collaborate with WHO’s Model list of essential medicines antibiotic working group to develop an evidence-based consensus and identify research priorities.

Abstracts in العربية, Français, Русский and Español at the end of each article.

Introduction

Global antibiotic consumption increased markedly between 2000 and 2010, with Brazil, China, India, the Russian Federation and South Africa accounting for 76% of the increase. In response, the World Health Organization (WHO) developed a global action plan on antimicrobial resistance in 2015. The fourth objective of this plan is to optimize the use of antibiotics. More recently, the classification of antibiotics in the WHO Model list of essential medicines has undergone substantial revision. The new AWaRe classification divides antibiotics into Access, Watch and Reserve antibiotic groups with the aim of encouraging their rational use and optimizing prescribing. Given this renewed focus on prudent antibiotic use, it is important that national prescribing guidelines are reviewed, any variations between countries are identified and the reasons for those variations are understood. Antimicrobials are the most commonly prescribed class of drugs for children.

Historically, however, paediatric dosing regimens have often been derived from pharmacokinetic data in adults, with the assumption that the relationship between drug exposure and total body weight is linear. This approach, although clinically widespread, is not supported by solid empirical evidence and may result in neonates and children being exposed to inappropriate systemic drug levels. The potential impact of inappropriate drug use in children on selection for antimicrobial resistance and the development of toxicity is unknown.

Clinicians’ prescribing practices are often informed by formularies, which recommend antibiotic doses that balance efficacy, toxicity and drivers of antimicrobial resistance. However, recommendations are frequently based on historical practice rather than evidence. For children, in particular, few data on efficacy, safety and pharmacokinetics are available.

Traditionally, there has been a preference for weight-based dosing strategies in the United States of America, whereas the United Kingdom of Great Britain and Northern Ireland has preferred age-banded dosing and WHO has preferred weight-banded dosing. This lack of standardization has resulted in widely varying recommendations and heterogeneous guidance, which have created ambiguities, especially for inexperienced clinicians. While there has tended to be some agreement on adult dosing guidance, for example between the National Institute for Health and Care Excellence in the United Kingdom and the Infectious Diseases Society of America in the United States, this has not been the case for children. Our view is that the international variation in guidance on paediatric dosing is most likely not based on different rates of antimicrobial resistance or clinical disease patterns, but instead reflects historical and cultural practices and the absence of a solid evidence base.

Although previous efforts have been made to compare local paediatric antibiotic guidelines, to the best of our knowledge there has been no detailed comparison of guidance from leading paediatric antibiotic formularies globally. Consequently, the aim of our study was to compare antibiotic guidance in the paediatric antibiotic formularies of both high-income countries and emerging economies for 32 commonly prescribed antibiotics on the 2017 WHO Model list of essential medicines for children.

Methods

We identified antibiotic guidelines that were either widely used internationally or originated in countries in which antibiotic use has increased markedly in recent years (i.e. Brazil, China, India, the Russian Federation and South Africa). In particular,
we looked for guidance in these countries that had been endorsed by national and international bodies by contacting national coordinators of the Global Antibiotic Resistance, Prescribing and Efficacy among Neonates and Children (GARPEC) network. Our aim was not to review all existing antibiotic guidance from every country comprehensively or to identify all patient management pathways. Instead, we selected guidelines that included specific paediatric dosing formulations or summaries, namely:  

i) Manual of childhood infections: the blue book, 4th edition, 2016, which is endorsed by the Royal College of Paediatrics and Child Health in the United Kingdom and the European Society of Paediatric Infectious Diseases and is a leading handbook used in Europe;  

ii) BNF (British national formulary) for children, 2017, which is a commonly used paediatric reference for prescribing in the United Kingdom;  

iii) Red book: 2018–2021 report of the committee on infectious diseases, 31st edition, which is endorsed by the American Academy of Paediatrics Committee on Infectious Diseases;  

iv) Pocket book of hospital care for children, second edition, 2013, from WHO, which is part of a series of documents and tools that support the integrated management of childhood illness; and  

v) Indian National treatment guidelines for antimicrobial use in infectious diseases, 2016, which were developed by the Indian National Centre for Disease Control.

Although we consulted national experts, we were unable to find paediatric antibiotic guidelines from Brazil, China, the Russian Federation or South Africa that were clearly endorsed nationally.

From each publication, we obtained the recommended dosage of all antibiotics listed in section: 6.2 (i.e. antibacterials) of the 2017 WHO Model list of essential medicines for children, with the exception of: (i) benzathine benzylpenicillin; (ii) procaine benzylpenicillin; (iii) cefixime; (iv) ticarcillin; (v) fosfomycin; (vi) daptomycin; (vii) polymyxins (e.g. colistin); (viii) fourth-generation cephalosporins, with or without a β-lactamase inhibitor (e.g. ceftriaxone). We included levofloxacin in our analysis even though it was not listed in the 2017 model list. We grouped the final selection of 32 antibiotics into the three AWaRe categories and compared dosing recommendations made by the different guidelines.

The BNF for children, in general, arranges guidance by route of administration and then by age band. The Blue book provides guidance by drug, giving the dose in milligrams per kilogram and the dosing frequency per day. The Red book presents separate tables for neonates and children, with neonatal doses stratified by gestational age and then by postnatal age (where applicable): paediatric recommendations are given as a total daily dose per kilogram with a frequency of administration. The Pocket book of hospital care for children presents separate summary tables for neonates and children; guidance on neonatal dosing is given by route of administration and stratified by age into the first week of life and a postnatal age of 2 to 4 weeks. The Indian National Centre for Disease Control guidelines present two dosing summary tables: (i) a dosing guide for commonly used antimicrobial agents; and (ii) drug doses in the paediatric age group. We primarily used information from the first table, as the second table was less complete. However, we consulted the second table and the text to resolve inconsistencies. The Indian guidance did not present a separate table for neonates.

Where possible, we present doses in mg/kg per day or mg/day along with dosing frequency to enable guidelines to be compared. When dosing guidance was given for specific syndromes or suspected causative organisms, we included those for priority syndromes (i.e. pneumonia, sepsis, acute otitis media, pharyngitis and urinary tract infection) and for severe infection, especially meningitis. We excluded prophylactic doses, loading doses and doses for nonpriority syndromes and for low- or very-low-birthweight infants. In all cases where the guidance provide in summary tables was unclear, we consulted the primary text.

Results

For all 32 antibiotics studied, there were differences in recommended dosages across the five guidelines (Table 1; available at: http://www.who.int/bulletin/volumes/98/6/19-234310). Of all the guidelines, the Pocket book gave dosing guidance for the fewest antibiotics reviewed (i.e. 12 of 32); it did not give recommendations for some commonly used Access (e.g. amoxicillin with clavulanic acid, phenoxymethylpenicillin and amikacin) and Watch (e.g. meropenem, piperacillin–tazobactam and vancomycin) antibiotics. In fact, it included guidance on only one antibiotic in the Watch group (i.e. erythromycin) and none in the Reserve group.

The number of dosing bands varied across guidelines, with the BNF for children tending to have the most and the Pocket book and the Indian National Centre for Disease Control guidelines having the fewest. The rationale for choosing different weight or age bands was not apparent, pharmacokinetic evidence was neither cited nor, if available, explained.

There was a considerable variation in recommended doses for each antibiotic. For example, Fig. 1 illustrates that the recommended dose of oral amoxicillin for a 5-year-old child weighing 18 kg with suspected nonsevere pneumonia varied from 360 mg per day (using the lower end of the Indian National Centre for Disease Control guidance of 20 mg/kg per day) to 1620 mg per day (using the upper end of the Blue book guidance of 90 mg/kg per day). Moreover, the five guidelines all proposed different age ranges for dosing and the suggested dosing interval was 6, 8 or 12 hours.

Discussion

We found marked differences between the guidelines reviewed on paediatric dosing recommendations for 32 commonly prescribed antibiotics. There were differences in the age basis for dosing (e.g. the use of postnatal age alone or in combination with weight or gestational age), the frequency of administration and the total daily dose. Although some of this heterogeneity may reflect differences between settings in epidemiology, risk factors, causative organisms (e.g. due to different vaccination policies) or patterns of antibiotic resistance and may therefore be appropriate, other variations (e.g. the use of different age or weight dosing bands) can create confusion. In many instances, it is difficult to discern the rationale behind
the dosing recommendations, whether they are derived from the accompanying summary of product characteristics, academic publications or expert consensus. Several national paediatric formularies, such as the Dutch, Italian and Spanish formularies, have been developed, but have been criticized for not presenting the underlying evidence or for referring to outdated paediatric dosing handbooks. However, the Dutch formulary has clearly tried to address this issue.

Variations between guidelines may partly be due to a lack of robust evidence on the best treatment. In addition, defining optimal drug dosing is more complex for children than adults: antibiotic doses must be adapted to maturational changes in pharmacokinetics and consider changes in pharmacodynamics, yet still be simple and pragmatic. However, few studies on antibiotic pharmacokinetics or effectiveness have been performed in children. Further, most of the guidelines we considered did not explicitly reference the evidence underlying their recommendations. The Blue book alone indicated the strength of the recommendations for each individual dose but did not present the supporting evidence. Moreover, the pharmacokinetic data underpinning many older off-patent antibiotics are very limited and were based on studies that were not conducted in accordance with recent standards.

A few strategic trials in children have examined high- and low-dose strategies and have reported efficacy and toxicity outcomes. However, these studies have used widely varying inclusion and exclusion criteria and end-points, which makes data synthesis between trials difficult. In addition, the absence of formal regulatory guidance on the design and conduct of antibiotic clinical trials in neonates and children has also hampered studies of clinical effectiveness. Our ability to compare therapies and treatment strategies would be improved by international collaboration to agree case definitions and outcome measures, similar to the collaboration that was effective in developing harmonized guidance for paediatric prescribing of antiretroviral drugs.

### Gaps in guidance

We identified several important omissions in global guidelines. First, we were unable to identify nationally endorsed, comprehensive treatment and dosing guidelines from Brazil, China, the Russian Federation or South Africa, although some individual institutions had their own local guidance. A unified approach within and, where appropriate, between countries would increase treatment standardization and make it easier to integrate the evidence. It is likely that many other countries, particularly low- and middle-income countries, also lack country-specific guidance and may have adopted recommendations developed elsewhere. In fact, published evidence often focuses on high-income settings, with little representation of low- or middle-income countries. However, guidelines developed in one country may not be appropriate for countries where the epidemiology and burden of infectious diseases is different. Second, further research is needed into clinical syndromes in which the antibiotic dose must be altered to take account of vary—

---

**Fig. 1.** Oral amoxicillin doses recommended by five guidelines for an 18-kg, 5-year-old child with suspected nonsevere pneumonia, 2018

| Pocket book<sup>a</sup> | 1440 mg orally, given in two divided doses |
|----------------------------|------------------------------------------|
| Red book<sup>b</sup> | 720–810 mg orally, given in three divided doses |
| Blue book<sup>c</sup> | 810–1620 mg orally, given in three divided doses |
| British national formulary for children<sup>d</sup> | 1500 mg orally, given in three divided doses |
| Indian National Centre for Disease Control<sup>e</sup> | 360–900 mg orally, given in three or four divided doses |

<sup>a</sup> Pocket book of hospital care for children, second edition.
<sup>b</sup> National treatment guidelines for antimicrobial use in infectious diseases.
<sup>c</sup> BNF (British national formulary) for children.
<sup>d</sup> Red book®. 2018–2021 report of the committee on infectious diseases, 31st edition.
<sup>e</sup> Manual of childhood infections: the blue book, 4th edition.

---

1. doi: http://dx.doi.org/10.2471/BLT.19.234310
ing levels of drug resistance. Finally, it should be recognized that European, United States’ and WHO guidelines were all developed at a similar time and were all based on the same rapidly and evolving evidence.

Conclusions

The wide variation in paediatric antibiotic dosing recommendations we found between leading formularies could be rectified by: (i) carrying out a systematic review of the pharmacokinetic and clinical evidence underpinning current global guidance on the most commonly used antibiotics in children; (ii) producing an evidence-based, transparent, consensus, guidance document on the optimal dosing of Access antibiotics based on current knowledge; and (iii) identifying antibiotics that should be a priority for future research because more evidence is needed to optimize paediatric dosing, the nature of the evidence needed should be clear. Interested global parties could be brought together under the auspices of WHO’s antibiotic working group on the Model List of Essential Medicines for Children to develop an evidence-based consensus and identify research priorities.3

Acknowledgements

We thank Jiaosheng Zhang (China), Ana Brett and Andre Ricardo Araujo da Silva (Brazil), Theoklis Zaoutis (United States of America), Olga Victorovna and Anna Turkova (Russian Federation), Ivet Angelova and Yasmine Yau.

Competing interests: MS is the chief editor of the Manual of childhood infections: the blue book and has been a clinical advisor to the BNF for children on anti-infectives. All other authors declare no competing interests.
Resumen

Comparación entre cinco recomendaciones de dosificación de antibióticos a uso pediátrico

Objetivo Compilar recomendaciones de dosificación de antibióticos en niños de varios países a través de diferentes fuentes publicadas. Es importante destacar que los países donde se han publicado las recomendaciones tienen un patrón de uso de antibióticos que varía, pero a nivel internacional sigue siendo un tema de gran interés. En el caso de los países con mayores índices de consumo de antibióticos, la dosificación varía notablemente, lo que plantea un reto en la atención médica pediátrica.

Resultados Se analizaron las recomendaciones de dosificación de antibióticos en niños de diversos países, destacándose la frecuencia con la que se utilizan los antibióticos en diferentes patrones de resistencia. El análisis subrayó la necesidad de una coordinación internacional para la elaboración de guías de uso de antibióticos más unificadas para mejorar la atención médica pediátrica.

Resumen

Una comparación de cinco recomendaciones sobre la dosificación pediátrica de los antibióticos

Objetivo Comparar las recomendaciones de dosificación de antibióticos en niños de varios países a través de diferentes fuentes publicadas. Es importante destacar que los países donde se han publicado las recomendaciones tienen un patrón de uso de antibióticos que varía, pero a nivel internacional sigue siendo un tema de gran interés. En el caso de los países con mayores índices de consumo de antibióticos, la dosificación varía notablemente, lo que plantea un reto en la atención médica pediátrica.

Resultados Se analizaron las recomendaciones de dosificación de antibióticos en niños de diversos países, destacándose la frecuencia con la que se utilizan los antibióticos en diferentes patrones de resistencia. El análisis subrayó la necesidad de una coordinación internacional para la elaboración de guías de uso de antibióticos más unificadas para mejorar la atención médica pediátrica.
infectious diseases). Se observó una marcada heterogeneidad en la dosificación recomendada (es decir, dosis diaria, grupos de dosificación por edad y frecuencia de la dosis) de los antibióticos más utilizados. En general, los motivos de las recomendaciones sobre la dosificación no estaban claros.

**Conclusión** Se deben mejorar las evidencias farmacocinéticas, farmacodinámicas y clínicas que respaldan la dosificación de los antibióticos pediátricos, en especial sobre las dosis totales y sobre los grupos de dosificación por edad o peso. Las investigaciones futuras deben considerar si las variaciones en las recomendaciones identificadas se derivan de diferentes patrones clínicos de la enfermedad, de niveles variables de resistencia a los antibióticos o de la disponibilidad de los medicamentos, más que de las preferencias históricas. Las partes interesadas a nivel mundial podrían colaborar con el grupo de trabajo sobre antibióticos de la *List model of medicamentos esenciales de la OMS* para desarrollar un consenso basado en las evidencias y para identificar las prioridades de investigación.

**References**

1. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014 Aug;14(8):742–50. doi: http://dx.doi.org/10.1016/S1473-3099(14)70807-7 PMID: 25022435

2. Global action plan on antimicrobial resistance. Geneva: World Health Organization. 2015. Available from: https://www.who.int/antimicrobial-resistance/publications/global-action-plan/en/ [2020 Apr 7]

3. Sharland M, Pulcini C, Harbarth S, Zeng M, Gandra S, Mathur S, et al.; 21st WHO Expert Committee on Selection and Use of Essential Medicines. Classifying antibiotics in the WHO Essential Medicines List for optimal use – be AWaRe. Lancet Infect Dis. 2018 0119(1):18–20. doi: http://dx.doi.org/10.1016/S1473-3099(17)30724-7 PMID: 29303731

4. WHO model list of essential medicines. 20th list. Geneva: World Health Organization. 2017. Available from: https://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf?ua=1 [2020 Apr 7]

5. Comolli S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al.; European Network for Drug Investigation in Children. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ. 2000 Jan 8;320(7227):79–82. doi: http://dx.doi.org/10.1136/bmj.320.7227.79 PMID: 10625257

6. Versporten A, Bienik J, Draper N, Sharland M, Goossens H; ARPEC project group. The Worldwide Antibiotic Resistance and Prescribing in European Children (ARPEC) point prevalence survey: developing hospital-quality indicators of antibiotic prescribing for children. J Antimicrob Chemother. 2016 Apr;71(4):1106–17. doi: http://dx.doi.org/10.1093/jac/dkv418 PMID: 26747104

7. Vernacchio L, Kelly JP, Kaufman DW, Mitchell AA. Medication use among small child still the best we can do? BMJ. 2011 12 15;343:d7803. doi: http://dx.doi.org/10.1136/bmj.d7803 PMID: 22174326

8. Pulcini C, Williams F, Molnari N, Davey P, Nathwani D. Junior doctors’ knowledge and perceptions of antibiotic resistance and prescribing: a survey in France and Scotland. Clin Microbiol Infect. 2015 Apr;21(4):354–61. doi: http://dx.doi.org/10.1016/S1473-3099(15)00095-3 PMID: 25865823

9. Bielicki JA, Barker CJ, Saxena S, Wong IC, Long PF; Sharland M. Not too little, not too much: problems of selecting oral antibiotic dose for children. BMJ. 2015 11 3;351:h5447. doi: http://dx.doi.org/10.1136/bmj.h5447 PMID: 26637515

10. Folgori L, Bielicki J, Ruiz B, Turner MA, Bradley JS, Benjamin D, et al. Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. Lancet Infect Dis. 2016 09;16(9):e178–89. doi: http://dx.doi.org/10.1016/S1473-3099(16)00069-4 PMID: 27357212

11. Pansa P, Hisa Y, Bielicki J, Lutsar I, Walker AS, Sharland M, et al. Evaluating safety reporting in paediatric antibiotic trials, 2000–2016: a systematic review and meta-analysis. Drugs. 2018 Feb;78(2):231–44. doi: http://dx.doi.org/10.1007/s40265-017-0850-x PMID: 29218501

12. Thompson G, Barker CJ, Folgori L, Bielicki JA, Bradley JS, Lutsar I, et al. Global shortage of neonatal and paediatric antibiotic trials: rapid review. BMJ Open. 2017 10 13;7(10):e016293. doi: http://dx.doi.org/10.1136/bmjopen-2017-016293 PMID: 29030411

13. Pulcini C, Wencker F, Friimodt-Møller N, Kern WV, Nathwani D, Rodriguez-Baño J, et al.; ESGAP Curriculum Working Group. European survey on principles of prudent antibiotic prescribing teaching in undergraduate students. Clin Microbiol Infect. 2015 Apr;21(4):354–61. doi: http://dx.doi.org/10.1016/cmi.2014.11.015 PMID: 25685823

14. Bielicki JA, Barker CJ, Saxena S, Wong IC, Long PF; Sharland M. Antibiotic prescribing guidelines [internet]. London: National Institute for Health and Care Excellence; 2020. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/antimicrobial-prescribing-guidelines [cited 2020 Mar 30].

15. Thompson G, Barker CJ, Folgori L, Bielicki JA, Bradley JS, Lutsar I, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014 Aug;14(8):742–50. doi: http://dx.doi.org/10.1016/S1473-3099(14)70014-9 PMID: 25022435

16. Spyridis N, Syridou G, Goossens H, Versporten A, Kopsidas J, Kourlaba G, et al.; ARPEC Project Group Members. Variation in paediatric hospital antibiotic guidelines in Europe. Arch Dis Child. 2016 Jan;101(1):72–6. doi: http://dx.doi.org/10.1136/archdischild-2015-308255 PMID: 26416900

17. Thompson G, Barker CJ, Folgori L, Bielicki JA, Bradley JS, Lutsar I, et al. Global shortage of neonatal and paediatric antibiotic trials: rapid review. BMJ Open. 2017 10 13;7(10):e016293. doi: http://dx.doi.org/10.1136/bmjopen-2017-016293 PMID: 29030411

18. Pulcini C, Wencker F, Friimodt-Møller N, Kern WV, Nathwani D, Rodriguez-Baño J, et al.; ESGAP Curriculum Working Group. European survey on principles of prudent antibiotic prescribing teaching in undergraduate students. Clin Microbiol Infect. 2015 Apr;21(4):354–61. doi: http://dx.doi.org/10.1016/cmi.2014.11.015 PMID: 25685823

19. Pulcini C, Williams F, Molnari N, Davey P, Nathwani D. Junior doctors’ knowledge and perceptions of antibiotic resistance and prescribing: a survey in France and Scotland. Clin Microbiol Infect. 2015 Apr;21(4):354–61. doi: http://dx.doi.org/10.1016/j.cmi.2015.01.011 PMID: 26416900

20. IDSA practice guidelines [internet]. Arlington: Infectious Diseases Society of America; 2020. Available from: https://www.idsociety.org/practiceguidelines [cited 2020 Mar 30].

21. Spyridis N, Syridou G, Goossens H, Versporten A, Kopsidas J, Kourlaba G, et al.; ARPEC Project Group Members. Variation in paediatric hospital antibiotic guidelines in Europe. Arch Dis Child. 2016 Jan;101(1):72–6. doi: http://dx.doi.org/10.1136/archdischild-2015-308255 PMID: 26416900

22. Global antibiotic resistance, prescribing, and efficacy among neonates and children (GARPEC) [internet]. Padova: Penta Child Health Research; 2020. Available from: https://penta-id.org/antimicrobials/garpec/ [cited 2020 Mar 30].

23. Paediatric Formulary Committee. BMJ Group: Pharmaceutical, and RCPCH Publications, 2016.

24. Brady MT, Jackson MA, Kimberlin DW, Long SS, editors. Red book: 26th ed. Oxford: Oxford University Press; 2016.

25. de van Anker JN. Getting the dose of vancomycin right in the neonate. Int J Clin Pharmacol Ther. 2011 Apr;49(4):247–9. doi: http://dx.doi.org/10.5141/ CPPh49247 PMID: 21429437

26. Bartelink IL, Wulff T, Jonker M, de Vos M, Egberts TC, Ververs TT, et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother. 2013 Jan;57(1):235–40. doi: http://dx.doi.org/10.1128/AAC.01540-12 PMID: 23114771
29. Barker CI, Standing JF, Turner MA, McElnay JC, Sharland M. Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies – and when is enough data enough? Curr Opin Infect Dis. 2012 Jun;25(3):235–42. doi: http://dx.doi.org/10.1097/QCO.0b013e328353105c PMID: 22517604

30. Piñeiro Pérez R, Martínez Fernández-Llamazares C, Calvo Rey C, Piñeiro Pérez AP, Criado Vega EA, Bravo Acuria J, et al. Pediamécum: un año de experiencia. [Pediamécum: one year of experience]. An Pediatr (Barc). 2014 Oct;81(4):257.e1–6. Spanish. doi: http://dx.doi.org/10.1016/j.anpedi.2014.02.023 PMID: 24857432

31. van der Zanden TM, de Wildt SN, Liem Y, Offringa M, de Hoog M, Dutch Paediatric Pharmacotherapy Expertise Network NKFK (Nederlands Kenniscentrum voor Farmacotherapie bij Kinderen). Developing a paediatric drug formulary for the Netherlands. Arch Dis Child. 2017 04;102(4):357–61. doi: http://dx.doi.org/10.1136/archdischild-2016-311674 PMID: 27799154

32. Kinderformularium [internet]. Rotterdam: Nederlands Kenniscentrum Farmacotherapie bij Kinderen (NKFK); 2020. Dutch. Available from: https://www.kinderformularium.nl/ [cited 2020 Mar 30].

33. Porta A, Hsia Y, Doerholt K, Spyridis N, Bielicki J, Menson E, et al. Comparing neonatal and paediatric antibiotic prescribing between hospitals: a new algorithm to help international benchmarking. J Antimicrob Chemother. 2012 May;67(5):1278–86. doi: http://dx.doi.org/10.1093/jac/dks021 PMID: 22378680

34. Folgori L, Bielicki J, Ruiz B, Turner MA, Bradley JS, Benjamin DK Jr, et al. Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. Lancet Infect Dis. 2016 09;16(9):e178–89. doi: http://dx.doi.org/10.1016/S1473-3099(16)00089-4 PMID: 27375212

35. Bamford A, Turkova A, Lyall H, Foster C, Klein N, Bastaans D, et al.; PENTA Steering Committee. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life. HIV Med. 2018 01;19(1):e1–42. doi: http://dx.doi.org/10.1111/hiv.12217 PMID: 25649230

36. Kuehn J, Ismael Z, Long PF, Barker CI, Sharland M. Reported rates of diarrhea following oral penicillin therapy in pediatric clinical trials. J Pediatr Pharmacol Ther. 2015 Mar-Apr;20(2):90–104. PMID: 25964726
Table 1. Dosing recommendations in five widely used, guidelines for 32 commonly prescribed, paediatric antibiotic formulations, 2018

| Antibiotic | BNF for children* | Blue book® | Red book® | Pocket book® | Indian National Centre for Disease Control® |
|------------|-------------------|-------------|-----------|--------------|------------------------------------------|
| **Amikacin** | Neonate: • intravenous, 15 mg/kg per day, q12h; 1 month – 11 years: • intravenous, 15 mg/kg per day, q12h; 12–17 years: • intravenous, 15 mg/kg per day, q12h | 7 days | 7 days (GA: ≥ 35 weeks): • intramuscular/intravenous, 15 mg/kg per day, q24h; > 7 days (GA: ≥ 35 weeks): • intramuscular/intravenous, 15 mg/kg per day, q36h (GA: < 30 weeks); ≤ 14 days: • intramuscular/intravenous, 15 mg/kg per day, q48h (GA: < 30 weeks); ≤ 14–28 days: • intramuscular/intravenous, 15 mg/kg per day, q48h (GA: ≥ 30–34 weeks); > 28 days: • intramuscular/intravenous, 15–22.5 mg/kg per day, q8h–q12h | No information | No information |

Amoxicillin | < 7 days: • intravenous, 60 mg/kg per day, q12h; 7 days – 1 month: • oral/intravenous, 90 mg/kg per day, q8h; > 1–11 months: • oral, 757 mg/day, q8h; 1–4 years: • oral, 758 mg/day, q8h; Child: • intravenous, 60–90 mg/kg per day, q8h; 5–11 years: • oral, 1100 mg/day, q8h; 12–17 years: • oral, 1100 mg/day, q8h | < 28 days: • oral/intravenous, 60–120 mg/kg per day, q12h; 7–28 days: • oral/intravenous, 90–180 mg/kg per day, q8h; 1 month – 18 years: • oral, 45–90 mg/kg per day, q8h; intravenous, 90–180 mg/kg per day, q8h | < 28 days – 11 years: • oral, 40–45 mg/kg per day, q8h (standard dose); • oral, 80–90 mg/kg per day, q12h (high dose); • oral, 90 mg/kg per day, q24h (acute otitis media); • oral, 50 mg/kg per day, q24h (streptococcal pharyngitis); > 12 years: • oral, 775 mg/day (extended-release formulation), q24h | No information | No information |

Amoxicillin with clavulanic acid | Neonate: • oral, 0.75 mL/kg per day (125/31 suspension), q8h; intravenous, 60 mg/kg per day, q12h; 1–2 months: • intravenous, 60 mg/kg per day, q12h; 1–11 months: • oral, 0.75 mL/kg per day (125/31 suspension), q8h; 3 months – 17 years: • intravenous, 90 mg/kg per day, q8h; 1–5 years: • oral, 0.75 mL/kg per day (125/31 suspension), q8h; 6–11 years: • oral, 0.65 mL/kg per day (250/62 suspension), q8h; 12–17 years: • oral, 0.75 mL/day (250/62 suspension), q8h | < 28 days: • oral/intravenous, 60–120 mg/kg per day, q12h; 7–28 days: • oral/intravenous, 90–180 mg/kg per day, q8h; 1 month – 6 years: • oral, 0.75–1.5 mL/kg per day (125/31 suspension), q8h; 2 months – 18 years: • oral, 0.3–0.4 mL/kg per day (400/57 suspension), q12h; 3 months – 18 years: • intravenous, 90–120 mg/kg per day, q8h–q12h; 6–12 years: • oral, 0.3–0.9 mL/kg per day (250/62 suspension), q8h; 12–18 years: • oral, 250–1250 mg tablet, q8h; • oral, 500–1250 mg tablet, q8h (severe infection) | > 28 days: • oral, 90 mg/kg per day (14–1 formulation), q12h; • oral, 25–45 mg/kg per day (7–1 formulation), q12h; • oral, 20–40 mg/kg per day (4–1 formulation), q8h | No information | No information |

Ampicillin | < 7 days: • intravenous, 60 mg/kg per day, q12h; 7–20 days: • oral/intravenous, 90 mg/kg per day, q8h; 21–28 days: • oral/intravenous, 120 mg/kg per day, q8h; 1 month – 18 years: • intravenous, 150 mg/kg per day, q8h; 1–4 years: • oral, 500 mg/day, q8h; 5–11 years: • oral, 1000 mg/day, q8h; 12–17 years: • oral, 2000 mg/day, q8h | 7 days: • oral/intravenous, 60–120 mg/kg per day, q12h; 7–21 days: • oral/intravenous, 90–180 mg/kg per day, q12h; 21 days – 1 month: • oral/intravenous, 120–240 mg/kg per day, q8h; 1 month – 18 years: • oral, 60–120 mg/kg per day, q8h; intravenous, 100 mg/kg per day, q8h; intravenous, 200 mg/kg per day, q6h (severe infection); • intravenous, 600 mg/kg per day, q4h (meningitis) | ≤ 7 days: • intramuscular/intravenous, 10 mg/kg per day, q12h; • intramuscular/intravenous, 10 mg/kg per day, q24h (GA: ≥ 34 weeks); ≤ 7–28 days (GA: ≤ 34 weeks): • intramuscular/intravenous, 15 mg/kg per day, q12h; • intramuscular/intravenous, 15 mg/kg per day, q24h (GA: ≥ 34 weeks); ≤ 8–28 days: • intramuscular/intravenous, 20 mg/kg per day, q8h; > 2 months: • intramuscular/intravenous, 200 mg/kg per day, q8h | No information | No information |

Ampicillin with clavulanic acid | < 7 days: • intravenous, 60 mg/kg per day, q12h; 7–20 days: • oral/intravenous, 90 mg/kg per day, q8h; 21–28 days: • oral/intravenous, 120 mg/kg per day, q8h; 1 month – 18 years: • intravenous, 150 mg/kg per day, q8h; 1–4 years: • oral, 500 mg/day, q8h; 5–11 years: • oral, 1000 mg/day, q8h; 12–17 years: • oral, 2000 mg/day, q8h | 1 month – 12 years: • oral, 10 mg/kg per day, q24h (weight: < 15 kg); • oral, 200 mg/day, q24h (weight: 15–25 kg); • oral, 300 mg/day, q24h (weight: 26–35 kg); • oral, 400 mg/day, q24h (weight: 36–45 kg); • oral, 500 mg/day, q24h (weight: > 45 kg) | ≤ 28 days: • intravenous/oral, 10 mg/kg per day, q24h | No information | No information |

Ampicillin with clavulanic acid | 6 months – 17 years: • oral, 10 mg/kg per day, q24h; • oral, 200 mg/day, q24h (weight: 15–23 kg); • oral, 300 mg/day, q24h (weight: 26–35 kg); • oral, 400 mg/day, q24h (weight: 36–45 kg); • oral, 500 mg/day, q24h (weight: > 45 kg) | 1 month – 12 years: • oral, 10 mg/kg per day, q24h (weight: < 15 kg); • oral, 200 mg/day, q24h (weight: 15–25 kg); • oral, 300 mg/day, q24h (weight: 26–35 kg); • oral, 400 mg/day, q24h (weight: 36–45 kg); • oral, 500 mg/day, q24h (weight: > 45 kg) | ≤ 28 days: • intravenous/oral, 10 mg/kg per day, q24h | No information | No information |

(continues . . .)
### Antibiotic Guidelines, dosing recommendations, by age group, administration route, dosage, frequency

| Antibiotic | BNF for children | Blue book | Red book | Pocket book | Indian National Centre for Disease Control |
|------------|-----------------|-----------|----------|-------------|-------------------------------------------|
| **Aztreonam** | <7 days: | intravenous, 60 mg/kg per day, q12h; | ≥7 days: | intravenous, 30 mg/kg per day, q12h (GA: <32 weeks); | intravenous, 100–120 mg/kg per day, q24h; |
| | 7 days – 1 month: | intravenous, 90–120 mg/kg per day, q6h–q8h; | 7–14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| | > 1 month – 11 years: | intravenous, 90–120 mg/kg per day, q6h–q8h; | > 14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| | 12–17 years: | intravenous, 100–150 mg/kg per day, q6h–q8h; | ≥14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| **Benzylpenicillin** | <7 days: | intramuscular/intravenous, 50 mg/kg per day, q12h; | ≥7 days: | intravenous, 30 mg/kg per day, q12h (GA: <32 weeks); | intravenous, 100–120 mg/kg per day, q24h; |
| | 7–28 days: | intramuscular/intravenous, 75 mg/kg per day, q8h; | 7–14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| | Child: | intramuscular/intravenous, 100 mg/kg per day, q8h | > 14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| **Cefalexin** | <7 days: | oral, 50 mg/kg per day, q12h; | ≥7 days: | intravenous, 30 mg/kg per day, q12h (GA: <32 weeks); | intravenous, 100–120 mg/kg per day, q24h; |
| | 7–20 days: | oral, 75 mg/kg per day, q6h; | 7–14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| | 21–28 days: | oral, 100 mg/kg per day, q6h; | > 14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| | 1–11 months: | oral, 25 mg/kg per day, q12h; | > 14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| | 1–4 years: | oral, 25 mg/kg per day, q12h; | > 28 days: | intramuscular/intravenous, 155–200 mg/kg per day, q6h–q8h (meningitis) |
| | 5–11 years: | oral, 25 mg/kg per day, q12h; | > 28 days: | intramuscular/intravenous, 200 mg/kg per day, q6h–q8h (meningitis) |
| | 12–17 years: | oral, 1000–1500 mg/day, q8h–q12h | > 28 days: | intramuscular/intravenous, 200 mg/kg per day, q6h–q8h (meningitis) |
| **Cefazolin** | ≤ 7 days: | intravenous, 60 mg/kg per day, q12h; | ≥7 days: | intravenous, 30 mg/kg per day, q12h (GA: <32 weeks); | intravenous, 100–120 mg/kg per day, q24h; |
| | 7–21 days: | intravenous, 75–150 mg/kg per day, q8h; | 7–14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| | 21–28 days: | intravenous, 100–200 mg/kg per day, q6h–q8h; | > 14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| | 1 month – 18 years: | intravenous, 150–200 mg/kg per day, q6h–q8h | > 14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| | > 1 month – 11 years: | intravenous, 150–200 mg/kg per day, q6h–q8h (meningitis) |
| | Child: | oral, 100–150 mg/kg per day, q12h–q24h; | Child: | oral, 100–150 mg/kg per day, q12h–q24h; |
| | intramuscular/intravenous, 200–300 mg/kg per day, q6h–q12h (meningitis) | Intramuscular (penicillin G) | Intramuscular (penicillin G) | Intramuscular (penicillin G) | Intramuscular (penicillin G) |
| **Cefotaxime** | <7 days: | intramuscular/intravenous, 50 mg/kg per day, q12h; | ≥7 days: | intravenous, 30 mg/kg per day, q12h (GA: <32 weeks); | intravenous, 100–120 mg/kg per day, q24h; |
| | 7–20 days: | intramuscular/intravenous, 100 mg/kg per day, q12h; | 7–14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| | 21–28 days: | intramuscular/intravenous, 150 mg/kg per day, q8h; | > 14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| | 1–11 months: | intramuscular/intravenous, 150 mg/kg per day, q8h (meningitis); | > 14 days (GA: <32 weeks): | intravenous, 30 mg/kg per day, q8h (GA: >34 weeks); | intravenous, 100–120 mg/kg per day, q6h–q8h; |
| | 1–4 years: | intramuscular/intravenous, 150 mg/kg per day, q8h (meningitis); | > 28 days: | intramuscular/intravenous, 150–200 mg/kg per day, q6h (meningitis) |
| | 5–11 years: | intramuscular/intravenous, 150–200 mg/kg per day, q8h; | > 28 days: | intramuscular/intravenous, 200 mg/kg per day per day, q6h; |
| | 12–17 years: | intramuscular/intravenous, 200–300 mg/kg per day, q6h–q12h (meningitis) | > 28 days: | intramuscular/intravenous, 200 mg/kg per day per day, q6h; |
| | > 28 days: | oral, 25–50 mg/kg per day, q12h; | > 28 days: | intramuscular/intravenous, 200 mg/kg per day per day, q6h; |
| | oral, 75–100 mg/kg per day, q8h–q12h (bone or joint infection) | Oral (penicillin G procaine), q24h; | Oral (penicillin G procaine), q24h; | Oral (penicillin G procaine), q24h; | Oral (penicillin G procaine), q24h; |
| | oral, 50 mg/kg per day, q8h | Intramuscular, 50 000 IU/kg per day, q6h–q8h | Intramuscular, 50 000 IU/kg per day, q6h–q8h | Intramuscular, 50 000 IU/kg per day, q6h–q8h | Intramuscular, 50 000 IU/kg per day, q6h–q8h |
| | oral, 50–100 mg/kg per day, q6h–q12h; | > 2 months: | oral, 50–100 mg/kg per day, q6h–q8h |
| | oral, 100–200 mg/kg per day, q6h–q12h; | > 2 months: | oral, 100–200 mg/kg per day, q6h–q8h |
| | oral, 200 000 IU/kg per day, q6h–q8h | > 2 months: | oral, 200 000 IU/kg per day, q6h–q8h |
| | oral, 30–40 mg/kg per day, q8h | > 2 months: | oral, 30–40 mg/kg per day, q8h |

(continues...)
### Antibiotic Drug Dosages

| Drug | 0–4 weeks | 5 weeks – 1 month | 1–2 months | 2–5 months | 5–10 months | >1 year |
|------|------------|------------------|------------|------------|-------------|---------|
| Ceftriaxone | intramuscular/intravenous, 50–100 mg/kg per day, q12h | intramuscular/intravenous, 75–150 mg/kg per day, q8h | intramuscular/intravenous, 100 mg/kg per day, q12h | intramuscular/intravenous, 150 mg/kg per day, q8h | intramuscular/intravenous, 200 mg/kg per day, q24h | intravenous, 2000 mg/day, q24h |

### Additional Information

- **Ceftriaxone**: 
  - Intramuscular/intravenous, 50–100 mg/kg per day, q12h.
  - Intramuscular/intravenous, 75–150 mg/kg per day, q8h.
  - Intramuscular/intravenous, 100 mg/kg per day, q12h.
  - Intramuscular/intravenous, 150 mg/kg per day, q8h.
  - Intramuscular/intravenous, 200 mg/kg per day, q24h.

- **Ceftriaxone**: 
  - Intramuscular/intravenous, 50–100 mg/kg per day, q12h.
  - Intramuscular/intravenous, 75–150 mg/kg per day, q8h.
  - Intramuscular/intravenous, 100 mg/kg per day, q12h.
  - Intramuscular/intravenous, 150 mg/kg per day, q8h.
  - Intramuscular/intravenous, 200 mg/kg per day, q24h.

- **Ceftriaxone**: 
  - Intramuscular/intravenous, 50–100 mg/kg per day, q12h.
  - Intramuscular/intravenous, 75–150 mg/kg per day, q8h.
  - Intramuscular/intravenous, 100 mg/kg per day, q12h.
  - Intramuscular/intravenous, 150 mg/kg per day, q8h.
  - Intramuscular/intravenous, 200 mg/kg per day, q24h.

### Notes

- **Bull World Health Organ**: 2020;98:406–412.
- **Redbook**: No information.
- **BNF for children**: No information.
- **Blue book**: No information.
- **Indian National Centre for Disease Control**: No information.

---

*Note: This table provides a summary of antibiotic dosages for children, including age ranges and dosing recommendations for various antibiotics.*
Antibiotic | BNf for children® | Blue book® | Red book®** | Pocket book® | Indian National Centre for Disease Control®
---|---|---|---|---|---
Clindamycin | < 14 days: oral, 9–18 mg/kg per day, q6h; 14 days – 1 month: oral, 12–24 mg/kg per day, q6h; 1 month – 17 years: oral, 12–24 mg/kg per day, q6h; intramuscular/intravenous, 15–25 mg/kg per day, q6h | No information | No information | No information | oral/intravenous, 40–60 mg/kg per day, q6h–q8h
Cloxacillin, dicloxacillin or flucloxacillin | < 7 days: oral/intravenous, 50 mg/kg per day, q12h; 7–20 days: oral/intravenous, 75 mg/kg per day, q6h; 21–28 days: oral/intravenous, 100 mg/kg per day, q6h; 1 month – 1 year: oral, 250–500 mg/day, q6h; 2–9 years: oral, 500–1000 mg/day, q6h; 10–17 years: oral, 1000–2000 mg/day, q6h. Child: intramuscular/intravenous, 50–100 mg/kg per day, q6h | No information | No information | No information | oral, 50–100 mg/kg per day, q6h–q8h
Doxycycline | 12–17 years: oral, 100 mg/day, q24h | No information | No information | No information | oral, 50 mg/kg per day, q6h
Erythromycin | < 1 month: oral, 50 mg/kg per day, q6h; intravenous, 40–50 mg/kg per day, q6h; 1 month – 1 year: oral, 100 mg/day, q6h–q12h; 2–7 years: oral, 1000 mg/day, q6h–q12h; 8–17 years: oral, 1000–2000 mg/day, q6h–q12h; Child: intravenous, 50 mg/kg per day, q6h | No information | No information | No information | oral, 50 mg/kg per day, q6h
Gentamicin | 1 month – 11 years: oral/intravenous, 7.5 mg/kg per day, q8h; Child: intravenous, 7 mg/kg per day, q24h; 12–17 years: intramuscular/intravenous, 6 mg/kg per day, q8h | No information | No information | No information | oral/intravenous, 7–15 mg/kg per day, q6h–q8h
Imipenem with cilastatin | < 7 days: intravenous, 40 mg/kg per day, q12h; 7–20 days: intravenous, 60 mg/kg per day, q8h; 21–28 days: intravenous, 80 mg/kg per day, q8h; 1–2 months: intravenous, 80 mg/kg per day, q8h; 3 months – 17 years: intravenous, 60 mg/kg per day, q8h | No information | No information | No information | oral/intravenous, 100–200 mg/kg per day, q6h
Levofoxacin | No information | No information | No information | No information | No information | 6 months – 5 years: NRS, 20 mg/kg per day, q12h; > 5 years: NRS, 10 mg/kg per day, q24h

(continues...)

4120

doi: http://dx.doi.org/10.2471/BLT.19.234310
**Linezolid**

| ≤ 7 days: | oralintravenous, 20 mg/kg per day, q12h; |
| 7–28 days: | oralintravenous, 30 mg/kg per day, q8h; |
| 1 month – 11 years: | oralintravenous, 30 mg/kg per day, q8h; |
| 12–17 years: | oralintravenous, 1200 mg/day, q12h |

| ≤ 7 days: | oralintravenous, 20 mg/kg per day, q12h; |
| 7–28 days: | oralintravenous, 30 mg/kg per day, q8h; |
| 1 month – 12 years: | oralintravenous, 30 mg/kg per day, q8h; |
| ≥ 12–15 years: | oralintravenous, 1200 mg/day, q12h |

**Meropenem**

| ≤ 7 days: | oralintravenous, 40 mg/kg per day, q12h; |
| 7–28 days: | oralintravenous, 60 mg/kg per day, q8h; |
| 1 month – 11 years: | oralintravenous, 30–60 mg/kg per day, q8h (weight < 50 kg); |
| 12–17 years: | oralintravenous, 1500–3000 mg/day, q8h (weight ≥ 50 kg); |

| ≤ 7 days: | oralintravenous, 80 mg/kg per day, q12h; |
| 7–28 days: | oralintravenous, 120 mg/kg per day, q8h; |
| 1 month – 12 years: | oralintravenous, 30–120 mg/kg per day, q8h; |

| ≤ 7 days: | oralintravenous, 10 mg/kg per day, q12h (GA: < 34 weeks); |
| ≥ 7 days: | oralintravenous, 10 mg/kg per day, q8h (GA: ≥ 34 weeks); |
| ≥ 14 days: | oralintravenous, 20 mg/kg per day, q8h (GA: ≥ 34 weeks); |
| ≥ 28 days: | oralintravenous, 60 mg/kg per day, q8h; |

**Trimethoprim**

| ≤ 7 days: | oralintravenous, 20 mg/kg per day, q12h; |
| 7–28 days: | oralintravenous, 30 mg/kg per day, q8h; |
| 1 month – 11 years: | oralintravenous, 30 mg/kg per day, q8h; |
| 12–17 years: | oralintravenous, 1200 mg/day, q12h |

| ≤ 7 days: | oralintravenous, 10 mg/kg per day, q12h (GA: < 34 weeks); |
| ≥ 7 days: | oralintravenous, 10 mg/kg per day, q8h (GA: ≥ 34 weeks); |
| ≥ 14 days: | oralintravenous, 20 mg/kg per day, q8h (GA: ≥ 34 weeks); |
| ≥ 28 days: | oralintravenous, 60 mg/kg per day, q8h; |

(continues . . .)
| Antibiotic | BHf for children* | Blue book* | Red book** | Pocket book* | Indian National Centre for Disease Control® |
|------------|-------------------|------------|------------|--------------|------------------------------------------|
| Vancomycin |                   |            |            |              |                                          |
| Neonate:   |                   |            |            |              |                                          |
| • intravenous, 15 mg/kg per day, q24h (CGA: < 29 weeks); | | | | | |
| • intravenous, 30 mg/kg per day, q12h (CGA: 29–35 weeks); | | | | | |
| • intravenous, 45 mg/kg per day, q12h (CGA: > 35 weeks); | | | | | |
| Child:     |                   |            |            |              |                                          |
| • intravenous, 45 mg/kg per day, q8h | | | | | |
| Neonate:   |                   |            |            |              |                                          |
| < 28 days (GA: ≤ 28 weeks); | • NRS, 15 mg/kg per day, q24h (CrS: 0.5 mg/dL); | | | | |
| • NRS, 15 mg/kg per day, q12h (CrS: ≤ 0.5 mg/dL); | • NRS, 30 mg/kg per day, q12h (CrS: 0.5–0.9 mg/dL); | | | | |
| • NRS, 45 mg/kg per day, q8h (PMA: > 35 weeks); | • NRS, 10 mg/kg per day, q48h (CrS: > 1.4 mg/dL); | | | | |
| 1 month – 18 years: | • intravenous, 45 mg/kg per day, q8h | | | | |
| < 28 days (GA: > 28 weeks); | • NRS, 15 mg/kg per day, q12h (CrS: ≤ 0.5 mg/dL); | | | | |
| • NRS, 15 mg/kg per day, q24h (CrS: 0.7–0.9 mg/dL); | • NRS, 15 mg/kg per day, q24h (CrS: 0.9–1.1 mg/dL); | | | | |
| • NRS, 45 mg/kg per day, q8h (PMA: > 35 weeks); | • NRS, 15 mg/kg per day, q8h (PMA: > 35 weeks); | | | | |
| > 28 days: | • intravenous, 45–60 mg/kg per day, q6h-q8h; | | | | |
| < 28 days (GA: ≤ 28 weeks); | • NRS, 15 mg/kg per day, q12h (CrS: ≤ 0.5 mg/dL); | | | | |
| • NRS, 15 mg/kg per day, q24h (CrS: 0.5–0.9 mg/dL); | • NRS, 30 mg/kg per day, q12h (CrS: 0.5–0.9 mg/dL); | | | | |
| • NRS, 15 mg/kg per day, q24h (CrS: 0.9–1.1 mg/dL); | • NRS, 15 mg/kg per day, q24h (CrS: 1.1–1.4 mg/dL); | | | | |
| • NRS, 45 mg/kg per day, q8h (CrS: > 1.4 mg/dL); | • NRS, 15 mg/kg per day, q8h (CrS: > 1.4 mg/dL); | | | | |
| > 28 days: | • intravenous, 40–60 mg/kg per day, q6h–q8h | | | | |

CGA: corrected gestational age; CrS: serum creatinine; GA: gestational age; IU: international unit; NRS: no route of administration specified; PMA: postmenstrual age; PNA: postnatal age; q6h: every 6 hours; q8h: every 8 hours; q12h: every 12 hours; q24h: every 24 hours; q36h: every 36 hours; q48h: every 48 hours.

* BHf (British national formulary) for children.
* Manual of childhood infections: the blue book, 4th edition.
** Red book®: 2018–2021 report of the committee on infectious diseases, 31st edition.
* Pocket book of hospital care for children, second edition.
* National treatment guidelines for antimicrobial use in infectious diseases.